learndrugs
Hematologic

Disseminated Intravascular Coagulation

DIC Verified · Sep 2026

Disseminated intravascular coagulation is, as a 2026 review summarises the ISTH’s 2025 definition, "an acquired, life-threatening condition involving systemic coagulation activation, impaired fibrinolysis, and endothelial injury" — a process that consumes platelets and clotting factors, producing microvascular thrombosis and bleeding together, and always secondary to another condition.

The disorder behind the patient who is bleeding from every line site while microthrombi shut down their kidneys — the reason DIC is never the diagnosis, always the complication.

What’s going wrong in the body

The normal physiology, where it fails, and why the body’s compensation backfires.

01 Always a complication, never the diagnosis

The International Society on Thrombosis and Haemostasis defined DIC in its 2001 criteria as "an acquired syndrome characterized by intravascular activation of coagulation with loss of localization arising from different causes that can originate from and cause damage to the microvasculature" — and, as one review adds, "which if sufficiently severe, can produce organ dysfunction." Read that definition slowly, because two phrases do all the work. Acquired means something caused it. Loss of localization means the problem is not that clotting happens, but that it happens everywhere instead of at the one place it is needed.

The society updated that definition in 2025, and the new wording moves the emphasis — a 2026 review summarises it as: DIC "is now defined as an acquired, life-threatening condition involving systemic coagulation activation, impaired fibrinolysis, and endothelial injury." Two ideas the 2001 wording left implicit are now explicit — impaired fibrinolysis, which is the mechanism this page spends a whole block on, and endothelial injury, the glycocalyx damage that sepsis adds. The 2025 release also "emphasizes the condition’s dynamic nature, progressing from preclinical abnormalities to overt clinical manifestations such as bleeding and organ dysfunction," and it introduces a phase-based classification — pre-DIC, early-phase DIC, and overt DIC, where "early-phase DIC — also referred to as subclinical or compensated DIC — is characterized by laboratory abnormalities preceding clinical symptoms." Alongside the phases it names two phenotypes: thrombotic DIC, "marked by microvascular thrombosis and organ dysfunction," and hemorrhagic DIC, "characterized by bleeding due to consumption of coagulation factors." One honest caveat runs through the rest of this page: the full 2025 point table is not openly published, so the scoring walked through below is the 2001 version that this page’s sources carry.

The practical consequence is the single most important framing on this page: DIC is never a primary diagnosis. A review of four national DIC guidelines found them unanimous that "treatment of underlying conditions is recommended" and that "the diagnosis and treatment of DIC must therefore consider these underlying etiological features." The StatPearls chapter says it just as plainly: "the treatment for DIC centers on addressing the underlying disorder that ultimately led to this condition." You cannot fix DIC while the sepsis, the placental abruption, or the leukemia is still running — and a nurse who understands that will not expect the transfusion to be the cure.

Because DIC is secondary, it also inherits its behaviour from its cause, which is why the guideline literature sorts it by phenotype — what the coagulopathy is doing — rather than by severity alone. That axis sits alongside, not against, the 2025 phase classification above: the phases say how far the process has travelled, from pre-DIC through early-phase to overt, while the four treatment phenotypes below say what it is doing now and therefore what to give. A patient has one of each. The bleeding type is treated with blood transfusion plus synthetic protease inhibitors and antifibrinolytic therapy. The organ-failure (thrombotic) type is treated with natural protease inhibitors such as antithrombin and thrombomodulin, and antifibrinolytic therapy is not recommended. The massive-bleeding type gets transfusion and synthetic protease inhibitors, and heparin "is not recommended in patients with bleeding or massive bleeding type of DIC due to the increased risk of bleeding." The non-symptomatic (pre-DIC) type is where "treatment with heparin is recommended," and it is diagnosed on hemostatic molecular markers rather than on bleeding. Each drug decision on this page hangs on which phenotype is in front of you.

02 Tissue factor lights the fuse — and the brakes burn with the fuel

Step one: tissue factor. Tissue factor "is expressed on macrophages, monocytes, and endothelial cells and plays a central role in the development of coagulopathy and DIC in sepsis." It "activates coagulation factor VII to VIIa in the coagulation pathway. Via the extrinsic pathway, thrombin and fibrin are formed, forming clots in the circulation." The trigger differs by cause — endotoxin in sepsis, exposed tissue in trauma, and in acute promyelocytic leukemia the malignant cells themselves drive the coagulopathy. The pathway is the same wherever the spark comes from.

Step two: the loop closes. "As this process continues, thrombin and fibrin further impair the coagulation cascade through positive feedback loop stimulation and coagulation inhibitor consumption," with dysregulation of "the protein C system and antithrombin III." This is the part students most often miss: the body’s natural anticoagulants — the brakes — are consumed at the same time as the clotting factors. The system loses both its fuel and its ability to stop.

Step three: consumption produces the bleeding. Clotting factors are used up in the microvasculature and "platelets may also become trapped and consumed." Here is the paradox that defines the disease: the patient who is clotting everywhere simultaneously cannot clot where it matters. Nothing has gone wrong with the platelets or factors that remain — there are simply not enough of them left, because they were spent in vessels too small to see.

Step four: the microthrombi damage organs. Widespread microvascular clotting compromises blood flow and "ultimately result[s] in multiple organ dysfunction syndrome" — it "can quickly lead to multiorgan failure and death." Sepsis adds two specific amplifiers worth naming: neutrophil extracellular traps — NETs, "consisting of DNA, histones and granule proteins released from activated neutrophils and other granulocytes, have been implicated in thrombus formation" — and endothelial injury, since "one of the unique features of sepsis-associated DIC is endothelial injury," with shedding of the glycocalyx, "the gel-like thin layer that covers the vascular endothelium." Strip that layer and the vessel wall itself becomes a clotting surface.

One chain produces both halves of the disease: tissue factor drives thrombin generation that both throws microthrombi into organs and consumes the platelets, factors, and natural anticoagulants the patient needs to stop bleeding.

03 Why the same disease bleeds in one patient and clots in another

Two patients with DIC can look like opposite diseases, and the mechanism review explains why in terms of a single enzyme system. Sepsis-associated DIC begins with a transient burst of fibrinolysis driven by endothelial t-PA release — and then shuts it off: PAI-1 rises, and "the marked increase in the PAI-1 level leads to disrupted fibrinolysis, and this key event represents the typical feature of thrombotic-type DIC." With fibrinolysis suppressed, the fibrin that has been laid down in the microcirculation stays there, and the patient’s dominant problem is organ failure. By contrast, "suppression of fibrinolysis in sepsis-associated DIC does not routinely occur in nonseptic DIC" — in placental abruption, for example, the coagulopathy is "followed soon after by massive bleeding as a result of consumptive coagulopathy", and the visible problem is hemorrhage.

This matters more than a piece of trivia, because it inverts a piece of classic teaching. The familiar phrase "microthrombi then secondary fibrinolysis causes the bleeding" holds for some presentations but is the opposite of what the sources describe in the sepsis-associated, thrombotic phenotype, where fibrinolysis is suppressed, not amplified. The safer framing is the phenotype split itself: ask which arm this patient is on before predicting what will happen next, and before choosing a drug.

The two arms also explain why every treatment on this page is a trap when given to the wrong phenotype. Heparin, given in the bleeding or massive-bleeding type, worsens bleeding. Antifibrinolytics, given in the organ-failure type, worsen thrombosis. The same two drugs are correct therapy on the other arm. Note also that the fetched sources do not use the labels "acute DIC" and "chronic DIC" — the StatPearls chapter explicitly does not distinguish them — so the four phenotypes, not a time-based split, are the vocabulary to carry.

The fate of fibrinolysis decides which disease the patient has — and therefore which of two opposite treatments is correct.

04 Reading the labs — the trend is the diagnosis

Five results define DIC, and each carries a caveat the classic list leaves out. Platelets fall — it is "the commonest laboratory diagnostic feature of DIC," though non-specific, and platelet activation can create "inaccuracy when using automated platelet counting." PT prolongs, and PT is the test to watch: "the ISTH DIC Subcommittee recommends PT as the coagulation test of choice," because "aPTT can be shortened owing to increased Factor VIII levels from the acute phase response, aPTT prolongation may lag behind the clinical manifestations." Fibrinogen falls — but a single normal value proves nothing, because absolute low fibrinogen has a "low sensitivity (22%)" and fibrinogen "is also an acute-phase reactant," so it can start high and be falling fast while still reading normal. D-dimer and fibrin degradation products rise with "high sensitivity but low specificity," and "different commercial assays have different normal ranges, which are not interchangeable." Schistocytes appear on the smear — red cells shredded as they squeeze past intravascular fibrin strands, the morphologic signature of thrombotic microangiopathy.

Which leads to the most nurse-actionable fact on this page: serial testing is the diagnosis, not a single panel. "A combination of results at different time points is particularly helpful in determining the presence of DIC," and clinicians should perform "serial monitoring" and remain "vigilant" for worsening trends even when initial values appear normal, which provides "a safeguard for the early recognition of DIC." A fibrinogen of 1.4 g/L is unremarkable on its own and alarming if yesterday it was 3.2. The nurse who notices the direction of travel finds DIC before the score does.

The ISTH 2001 overt DIC score formalizes that panel, and it is applied only when the patient already has a condition known to cause DIC. Platelet count: 100 × 10⁹/L or above = 0, below 100 = 1, below 50 = 2. D-dimer or FDP elevation: no increase = 0, moderate = 2, strong = 3. PT prolongation: under 3 seconds = 0, 3 to under 6 seconds = 1, 6 seconds or more = 2. Fibrinogen: 1 g/L or above = 0, below 1 g/L = 1. A score of 5 or more is "compatible with overt DIC"; below 5 suggests non-overt DIC. Be honest about what the score is worth, and be precise about where. DIC scoring systems are reported to have "a sensitivity of ≈90% and a specificity of ≈97%," and a validation study found an overall positive predictive value of 68% at a score of 5 or more. But stratified by score that figure splits sharply: 47% at a score of exactly 5, 68% at 6, and 88% at 7 or above. In other words, at the very cutoff the score teaches as "compatible with overt DIC," fewer than half of the patients it labels turn out to have DIC. A borderline 5 is much weaker evidence than the headline number suggests. For sepsis there is an earlier-warning alternative, the sepsis-induced coagulopathy (SIC) score, built from platelet count, PT ratio, and the SOFA score with a threshold of 4 points, which "was more sensitive than the ISTH criteria to detect coagulopathy." The 2025 update formalizes that role — "the sepsis-induced coagulopathy score is now acknowledged as a tool for detecting early-phase DIC in septic patients" — and tailors the criteria "to the underlying disease, such as sepsis, trauma, or malignancy."

What changed in the 2025 scoring, and what this page cannot tell you. The revision "refined" the overt-DIC score, and the one component whose new values are on record is D-dimer: levels more than 3 times and more than 7 times the upper limit of normal now score 2 and 3 points. Platelet count, prothrombin time expressed as INR, and fibrinogen remain key indicators. Beyond that, the full 2025 point table is not openly published, so this page walks through the 2001 score its sources carry; the 2025 update’s stated change is the D-dimer anchor, and platelet count, prothrombin time and fibrinogen remain key indicators. Treat the worked example below as the 2001 score, and expect the numbers to move when the 2025 table is available.

The ISTH overt DIC score assembled from four serial laboratory values — applied only to a patient who already has a condition known to cause DIC, and honest about its own predictive value.

Causes & risk factors

Modifiable factors are teaching targets — the patient can act on them.

Sepsis — the most common cause; DIC occurs in up to 30% to 50% of cases of severe sepsis Malignancy — up to 20% of patients with metastatic adenocarcinoma or lymphoproliferative disease Acute promyelocytic leukemia — the leukemia that presents as a coagulation emergency Placental abruption HELLP syndrome Amniotic fluid embolism Trauma and surgery — approximately 15.5% of DIC cases follow surgery Pancreatitis Snake bites Liver disease Transplant rejection Transfusion reactions

Signs & symptoms

Each finding tied to the mechanism that produces it — and the triage it calls for.

Bleeding from several unrelated sites at once — gingiva, surgical or trauma sites, vagina, rectum, and around devices such as cannulas, arterial lines and urinary catheters early Report immediately
Why: Platelets and clotting factors have been consumed in the microvasculature, so nothing seals anywhere. The number of separate, unrelated sites is what distinguishes DIC from a local surgical bleed — one oozing wound is surgery, four oozing sites is a coagulopathy. In practice the line and cannula sites are the earliest cue most nurses will see, because they are inspected more often than gums.
Organ dysfunction without visible bleeding — the thrombotic phenotype Hold & notify
Why: In sepsis-associated DIC, rising PAI-1 shuts fibrinolysis down, so fibrin laid into the microcirculation stays there and the dominant problem is organ failure rather than hemorrhage. A patient can be deep in DIC with nothing on the sheets, which is why the clotting arm has to be sought rather than waited for.
Widespread purpura, petechiae, and ecchymoses Hold & notify
Why: Consumptive thrombocytopenia lets capillary leaks go unplugged. In immune thrombocytopenia, oral purpura and gross hematuria "may precede severe hemorrhage" — a warning worth borrowing in any consumptive thrombocytopenia: they are warnings, not endpoints, which is exactly why they are reported rather than watched.
Hematomas and jaundice late Hold & notify
Why: Bleeding into tissue once factor consumption is advanced, and jaundice reflecting the hemolysis and hepatic involvement that accompany severe disease. Frank hemorrhage from multiple sites is the emergency above; these are the findings that say the consumption is deepening.
Skin necrosis, gangrene, and cyanosis of the extremities late Report immediately
Why: The thrombotic arm of the same disease — microthrombi shut down the distal circulation. Clots "can reduce or block blood flow, which can damage organs," and it is happening in the same patient who is bleeding.
Falling urine output, then oliguria or anuria, with hematuria Report immediately
Why: Renal microthrombi plus hypoperfusion. Read this as an organ-failure cue, not a fluid cue — the response is escalation, not simply more intravenous fluid.
New confusion or a change in level of consciousness Report immediately
Why: Cerebral microvascular occlusion and hypoperfusion; the sources also list stroke among the complications. A change in mental status in a septic or postpartum patient who is oozing is an escalation trigger in its own right.
Dyspnea and hemoptysis Hold & notify
Why: Pulmonary microvascular involvement with bleeding into the airways — the lungs manifest both arms of the disease at once. Report promptly; escalate as an emergency if oxygenation or hemodynamics fall with it.
Chest pain Hold & notify
Why: Coronary microvascular involvement. In a patient already being treated for sepsis or trauma it is easily attributed elsewhere, which is exactly why it belongs on the DIC cue list rather than being explained away.
A falling blood pressure — shock is a named complication Hold & notify
Why: Blood loss on top of the underlying illness, in a patient whose vasculature is also being obstructed. The hypotension is often read as the primary problem worsening rather than as a new coagulopathy declaring itself — report it as a change, and treat frank circulatory collapse as the emergency it is.
Platelets, PT, fibrinogen, and D-dimer all moving in the wrong direction together early Hold & notify
Why: The laboratory manifestation of the disease, and the one most likely to be noticed first. Individually each value may still sit inside its reference range; moving as a set, over hours, they are the diagnosis.
Oral mucosal hemorrhage, purpura, and extremity petechiae in a newly diagnosed leukemia Report immediately
Why: The presentation of acute promyelocytic leukemia, where the leukemic cells themselves drive the coagulopathy — suspected APL is to be "immediately hospitalized and managed as a medical emergency."

Diagnostics

Test In this disorder Normal
Platelet count Non-specific on its own, and platelet activation in DIC can create "inaccuracy when using automated platelet counting." The falling trend matters more than any single value Falling — "the commonest laboratory diagnostic feature of DIC" —
Prothrombin time (PT) The ISTH DIC Subcommittee "recommends PT as the coagulation test of choice," because "aPTT can be shortened owing to increased Factor VIII levels from the acute phase response, aPTT prolongation may lag behind the clinical manifestations." Both are prolonged in established DIC, but aPTT can mislead early Prolonged — and this is the preferred coagulation test, not aPTT ISTH 2001 criteria (as reported by Annals of Laboratory Medicine) —
Fibrinogen Absolute low fibrinogen has a "low sensitivity (22%)," because fibrinogen "is also an acute-phase reactant" — it can start elevated and be consumed rapidly while still reading normal. Watch the decreasing level, not the threshold Falling — but a single normal value does not exclude DIC —
D-dimer / fibrin degradation products "Different commercial assays have different normal ranges, which are not interchangeable," and "increasing levels may be from renal and/or liver impairment affecting clearance." Compare a patient to their own previous result, not to another lab’s range Elevated — "high sensitivity but low specificity" —
Peripheral blood smear Red cells shredded as they pass intravascular fibrin strands; they "are characteristic of thrombotic microangiopathic conditions and reflect intravascular hemolysis." Their presence confirms that clotting is happening inside the vessels, not just that numbers are low Schistocytes — fragmented erythrocytes —
ISTH overt DIC score (2001 criteria) Applied only to a patient with an underlying condition known to cause DIC. Reported sensitivity ≈ 90% and specificity ≈ 97%, with an overall positive predictive value of 68% at a score of 5 or more — but stratified that is 47% at exactly 5, 68% at 6, and 88% at 7 or above, so a borderline score is far weaker evidence than the headline figure implies. The ISTH published an updated definition and diagnostic criteria in 2025; its full point table is not openly published, so this row teaches the 2001 criteria the page’s sources carry. On record from the update: D-dimer above 3× and above 7× the upper normal limit now score 2 and 3 points, with platelets, PT-INR and fibrinogen remaining key indicators Platelets ≥ 100 × 10⁹/L = 0, < 100 = 1, < 50 = 2 · D-dimer/FDP no rise = 0, moderate = 2, strong = 3 · PT prolonged < 3 s = 0, 3 to < 6 s = 1, ≥ 6 s = 2 · fibrinogen ≥ 1 g/L = 0, < 1 g/L = 1. A score of 5 or more is compatible with overt DIC Score and cutoff: ISTH 2001 criteria (as reported by Annals of Laboratory Medicine and Res Pract Thromb Haemost). 2025 update: ISTH, via Iba et al., Semin Thromb Hemost 2026 —
Sepsis-induced coagulopathy (SIC) score The earlier-warning alternative in sepsis — it "was more sensitive than the ISTH criteria to detect coagulopathy," so it can flag the patient before the ISTH score does Built from platelet count, PT ratio, and the SOFA score; 4 or more points is required —
Antithrombin level Of limited use for early detection — "their sensitivity for early DIC is unclear as DIC is usually obvious from the global coagulation tests when levels are below 50% of normal." It also matters therapeutically: antithrombin concentrate must not be given with concomitant heparin Reduced, with significant reductions correlating with severity and outcome —

Complications

Warning: Multiple organ dysfunction syndrome Report immediately
Widespread microvascular thrombi compromise blood flow to kidneys, brain, lungs and heart — oliguria, confusion, dyspnea, chest pain — and DIC "can quickly lead to multiorgan failure and death."
This is the thrombotic arm doing its damage while attention is on the bleeding. DIC doubles the death rate of whatever caused it: "mortality rates have been shown to double in patients who are septic or those with severe trauma if they also have DIC." Because it affects multiple organ systems, "most survivors have a prolonged recovery period."
Warning: Uncontrolled hemorrhage Report immediately
Bleeding from multiple sites that will not stop, because the platelets and factors needed to stop it have been consumed elsewhere.
Two findings carry a borrowed advance warning: in immune thrombocytopenia, oral purpura and gross hematuria "may precede severe hemorrhage" — treat them the same way here. Patients and families need to understand "the importance of timely medical evaluation when new bleeding symptoms occur."
Warning: Digital and tissue ischemia — necrosis and gangrene Report immediately
Skin "necrosis, and gangrene," alongside the "widespread purpura, petechiae, and cyanosis" that excessive coagulation produces.
The same microthrombi that consume the clotting factors occlude the distal circulation. Assess perfusion of fingers, toes, ears and nose at every check — in a patient whose dominant problem looks like bleeding, the extremities are where the clotting arm becomes visible.
Warning: Stroke Report immediately
Named explicitly among the complications, and it presents as the new neurologic deficit or change in level of consciousness that is easy to attribute to sepsis or sedation.
A change in mental status in a septic or postpartum patient who is oozing has two possible explanations, and both are emergencies: cerebral microvascular occlusion, or intracranial bleeding into a patient who cannot clot. Either way it is escalated, not observed.
Caution: Treatment given to the wrong phenotype
The two main drug decisions in DIC are each harmful on the opposite arm of the disease.
Heparin "is not recommended in patients with bleeding or massive bleeding type of DIC due to the increased risk of bleeding," and in sepsis specifically "a meta-analysis of 9 trials demonstrated that in most patients with sepsis, heparin therapy does not reduce organ injury or mortality, but was associated with an increase in the risk of bleeding." Antifibrinolytics are for the bleeding phenotype — "the use of these drugs in patients with the organ failure or non-symptomatic type of DIC is generally not recommended." And antithrombin concentrate must be given without concomitant heparin, because heparin alters its protective effect.

Medications for this condition

Why each class is prescribed here — every card links to its full pharmacology page.

Anticoagulants High-alert
Cardiovascular · heparin

The heparin paradox: giving an anticoagulant to a patient who is bleeding from every line site is counter-intuitive, and the rationale is that the bleeding is driven by uncontrolled thrombin generation, so interrupting the clotting stops the consumption that causes the hemorrhage. The fetched evidence makes this strictly phenotype-dependent. Heparin is used when there is extensive clotting, in the non-symptomatic (pre-DIC) type, and as prophylaxis — "patients with DIC who are not actively bleeding should receive prophylactic anticoagulation with heparin or low molecular weight heparin." Heparin is not used in the bleeding or massive-bleeding types "due to the increased risk of bleeding." And in sepsis the evidence is actively unfavourable: a meta-analysis of nine trials found heparin "does not reduce organ injury or mortality, but was associated with an increase in the risk of bleeding." Where heparin is given for DIC, low molecular weight heparin is preferred over unfractionated. Two adjacent rules matter at the bedside: VTE prophylaxis is a separate question from treating DIC and has become standard of care, and antithrombin concentrate must be given without concomitant heparin, because heparin alters antithrombin’s protective effect.

Beyond medications

  • Treat the underlying cause — this is the treatment. Every guideline reviewed agrees that "treatment of underlying conditions is recommended," and DIC will not resolve while the sepsis, abruption, or malignancy continues. Source control, antibiotics, delivery, or chemotherapy is the therapy; everything else is support.
  • Platelet transfusion thresholds: platelets are given to DIC patients with active bleeding and a platelet count of 50 × 10⁹/L or below; a much lower threshold of 10 to 20 × 10⁹/L applies to patients who are not bleeding but at high risk. Both figures are corroborated across two sources.
  • Fresh frozen plasma for a "prolonged APTT or PT (greater than 1.5 times the normal value)," at an initial dose of 15 mL/kg — one source gives a range of 15 to 30 mL/kg — to replenish coagulation factors.
  • Cryoprecipitate or fibrinogen concentrate for "specific deficiencies in fibrinogen associated with the massive bleeding type." Note that no fetched source gives a numeric fibrinogen transfusion trigger for general DIC — the only numeric target is specific to acute promyelocytic leukemia.
  • Antithrombin concentrate and recombinant human soluble thrombomodulin are "recommended in patients with the organ failure type of DIC." A DIC-restricted meta-analysis showed a "beneficial effect of antithrombin on the mortality" (risk ratio 0.85), and thrombomodulin "significantly increased the rate of resolution of DIC," although mortality benefit was not statistically significant. Antithrombin must be given without concomitant heparin.
  • Antifibrinolytic therapy is reserved for the bleeding or major-bleeding phenotype and "is generally not recommended" in the organ-failure or non-symptomatic types. APL is not the easy exception it is often taught as. The four-guideline review notes that "One study of APL demonstrated a beneficial effect of antifibrinolytic agents in this situation" but that "cases complicated with severe thrombosis due to the combined use of ATRA and tranexamic acid have been documented," and current APL recommendations advise that tranexamic acid and other antifibrinolytics "should not be used routinely outside of the context of clinical trials."
  • In acute promyelocytic leukemia, ATRA is started on suspicion — "Treatment with ATRA should be started immediately when a diagnosis of APL is suspected" — because the coagulopathy is what kills. Supportive targets in APL specifically are a platelet count above 30 to 50 × 10⁹/L and a fibrinogen above 100 to 150 mg/dL (with an INR below 1.5). Watch for differentiation syndrome, for which corticosteroids (dexamethasone) are started "immediately at the earliest clinical suspicion."

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Assessment & monitoring
Do a full-body bleeding survey every shift and count the sites: gums, surgical wounds and drains, every cannula and arterial line, urinary catheter, vagina, rectum, and skin.
Why: The sources name these sites explicitly, and bleeding from several unrelated sites at once is the recognition cue that separates DIC from a local surgical bleed. One oozing wound is a wound; four oozing sites is a coagulopathy.
Treat urine output and mental status as organ-failure markers, not as fluid and comfort measures — and escalate a fall in either.
Why: Renal microthrombi and hypoperfusion produce oliguria and anuria, and cerebral involvement produces confusion and stroke. In a patient who is visibly bleeding, these are the two places the thrombotic arm of the same disease declares itself.
Track the trend across serial panels, not the single result: platelets, PT, fibrinogen, and D-dimer read together and over time.
Why: "A combination of results at different time points is particularly helpful in determining the presence of DIC," and serial monitoring provides "a safeguard for the early recognition of DIC" even when initial values look normal. A fibrinogen of 1.4 g/L is unremarkable alone and alarming if yesterday it was 3.2.
Know that a normal fibrinogen does not reassure, and that PT — not aPTT — is the coagulation test to watch.
Why: Absolute low fibrinogen has only 22% sensitivity because fibrinogen is an acute-phase reactant that can start high and fall fast. And aPTT "can be shortened owing to increased Factor VIII levels from the acute phase response," so its prolongation "may lag behind the clinical manifestations."
Assess perfusion of fingers, toes, ears and nose at each check, looking for cyanosis, necrosis or gangrene.
Why: The microthrombi that consume the clotting factors also occlude the distal circulation, — clots "can reduce or block blood flow, which can damage organs." In a patient whose obvious problem is bleeding, the extremities are where the clotting arm becomes visible first.
In the obstetric patient, assess and monitor lochia every 15 minutes in the immediate postpartum period, observe the surgical incision for bleeding and inflammatory signs, and perform rigorous fluid balance.
Why: This is the specific monitoring cadence the nursing literature sets for hemorrhage risk in this population, and DIC ranks among the common complications of HELLP syndrome requiring intensive care.
Interventions & safety
Establish and maintain patent large-calibre venous access early, while the patient can still be cannulated.
Why: This is a prepare-before-you-need-it action: "puncture and maintain patent large-caliber venous access" is the one procedural instruction in the fetched nursing literature, and every further puncture attempt in an established coagulopathy creates a new site that will not seal.
Apply bleeding precautions: soft-bristled toothbrush, injury-prevention measures in the environment, and gentle handling during all care.
Why: Consumed platelets and factors mean ordinary trauma becomes significant bleeding. These are the sourced precautions — note that "avoid intramuscular injections" and "avoid rectal temperatures," though widely taught, are not stated in any source for DIC.
Review every prescription and over-the-counter medication with the clinician, specifically screening out aspirin, NSAIDs, and ginkgo biloba.
Why: These impair platelet function in a patient whose platelet count is already falling — adding a functional platelet defect to a quantitative one.
Escalate immediately for oral purpura or gross hematuria.
Why: In immune thrombocytopenia, "Oral purpura and gross hematuria warrant special attention, as they may precede severe hemorrhage" — and in DIC the platelets are falling for a different reason but with the same bleeding risk. These are advance warnings rather than endpoints, and acting on them buys time that acting on frank hemorrhage does not.
Use aseptic technique when handling probes, drains and catheters, and minimize unnecessary punctures and invasive procedures.
Why: Every device site is a documented bleeding site in DIC — the sources list bleeding "through devices such as urinary catheters" alongside surgical and trauma sites. Fewer breaches means fewer places the patient cannot seal, and aseptic handling protects a patient whose underlying illness is often sepsis.
Know which drug belongs to which phenotype before administering it, and question an order that does not match the picture.
Why: Heparin in the bleeding or massive-bleeding type increases bleeding risk; antifibrinolytics in the organ-failure type increase thrombosis; and antithrombin concentrate must be given without concomitant heparin because heparin alters its protective effect. The same two drugs are correct therapy on the opposite arm of the disease.
Patient & family teaching
Explain that DIC is a complication of another illness, and that treating that illness is the treatment.
Why: Families watching transfusions run often believe the products are the cure and lose confidence when bleeding continues. Every guideline reviewed agrees that "treatment of underlying conditions is recommended" — the blood products buy time while the cause is addressed.
Teach the escalation rule plainly: new bleeding needs "timely medical evaluation," and signs of a clot — "chest pain, neurologic changes, or leg swelling" — mean seeking "emergency care promptly."
Why: The two halves cover both arms of the disease, and neither needs a judgement about how much blood is too much.
Teach the signs that warrant evaluation: petechiae, unexplained bruising, or mucosal bleeding.
Why: These are the low-threshold cues that appear before frank hemorrhage, and they are visible to a patient or family member who knows to look for them.
Teach that new confusion, chest pain, leg swelling, or a cold, dusky hand or foot must be reported — not just bleeding.
Why: The clotting arm of the same disease presents as a new deficit rather than a new bleed. Families primed to watch only for blood will miss the thrombotic half entirely.
Explain the medication rules to take home: no aspirin, NSAIDs, or ginkgo biloba, and clear every new product with the clinician.
Why: These impair platelet function, and over-the-counter analgesics are the most common way a recovering patient unknowingly reverses the gains of treatment.
Set expectations for recovery honestly: DIC affects multiple organ systems and most survivors have a prolonged recovery period.
Why: Even with optimal treatment DIC "carries a very high mortality rate," and its complications "can be life-threatening." Families who expect a quick recovery after the bleeding stops are unprepared for the organ-dysfunction phase that follows.

How a real nurse thinks

The clinical-judgment loop, worked for a typical presentation — reasoning, not reference.

  1. 1
    Recognize cues

    The cues that matter cluster into two groups that at first look unrelated. The bleeding group: oozing from four separate device sites plus the gums plus the abdominal dressing — that is bleeding from several unrelated sites at once, which is the recognition cue for a coagulopathy rather than a surgical bleed. The clotting group, easy to miss because attention is on the blood: dusky fingertips with sluggish refill, urine output down to about 24 mL/h from 45 mL/h, and a change in neurological responsiveness at the sedation hold. The laboratory cues move as a set: platelets falling 140 to 62, PT prolonged 4 seconds, fibrinogen 1.4 down to 0.8 g/L, D-dimer strongly up, and schistocytes on the smear. Note what the trend does that a snapshot would not: a fibrinogen of 1.4 g/L yesterday was already inside the normal range and told you nothing — falling to 0.8 is the finding.

  2. 2
    Analyze cues

    Score it. Platelets 62 — below 100 but not below 50 — scores 1. D-dimer strongly elevated scores 3. PT prolonged by 4 seconds — at least 3 but under 6 — scores 1. Fibrinogen 0.8 g/L, below 1 g/L, scores 1. Total 6, and a score of 5 or more is compatible with overt DIC. The prerequisite is satisfied before you even start: he has severe sepsis, a condition that causes DIC in up to 30% to 50% of severe cases, and the score is only applied to a patient who already has such a condition. Hold the score loosely, though, and hold it at the right number: at his score of 6 the positive predictive value is 68%, whereas at a bare 5 — the cutoff itself — it would be only 47%, rising to 88% at 7 or above. The score supports the clinical picture rather than replacing it. The schistocytes are the finding that confirms clotting is happening inside the vessels rather than that numbers are merely low. And the dusky fingers plus the falling urine output tell you this patient has both arms of the disease running at once.

  3. 3
    Prioritize

    The first priority is not a transfusion — it is the source. DIC is always secondary, and it will not resolve while the sepsis is unaddressed, so confirming that source control and antimicrobial therapy are adequate comes first and is the actual treatment. Second is escalation, because the combination of a coagulopathy, falling urine output, dusky digits and reduced responsiveness is multiple organ dysfunction declaring itself, and the drug decisions ahead are phenotype-dependent. Third is component support for the active bleeding. Fourth is protecting the sites he still has — large-bore access, minimal further punctures, gentle care. The oozing itself, though the most visible problem, is the symptom rather than the emergency.

  4. 4
    Generate solutions

    Component support follows the sourced thresholds. He is actively bleeding with platelets at 62 × 10⁹/L, so anticipate a platelet transfusion — the active-bleeding threshold is 50 × 10⁹/L or below, so this is a judgement call the team makes against the clinical picture rather than an automatic trigger, and the non-bleeding threshold of 10 to 20 × 10⁹/L clearly does not apply to him. His PT is prolonged and scores a point — but at a ratio of about 1.3 it sits below the sourced plasma trigger, which is a PT or aPTT "greater than 1.5 times the normal value," at which point fresh frozen plasma is given at 15 mL/kg. So plasma here is a clinical judgement rather than an automatic order, exactly as the platelet count is. Note how the two thresholds interlock: a PT that reached 1.5 times normal would generally mean about 6 seconds of prolongation, which would have scored 2 rather than 1 and pushed his total from 6 to 7. His fibrinogen is below 1 g/L, so cryoprecipitate or fibrinogen concentrate may follow if massive bleeding develops. On the drug question: this is the bleeding phenotype, so heparin is not indicated — "the administration of heparin is not recommended in patients with bleeding or massive bleeding type of DIC," and in sepsis specifically heparin "does not reduce organ injury or mortality, but was associated with an increase in the risk of bleeding." Nursing actions need no order: secure large-bore access now, apply bleeding precautions, hold non-essential punctures, and handle every device aseptically.

  5. 5
    Take action

    Do the no-order actions first: pressure and gentle dressings to the oozing sites, soft-swab oral care, secure and protect existing large-bore access, cluster care to avoid new punctures, and document the number and location of bleeding sites so the trend is visible to the next shift. Then escalate with the whole picture, not just the blood: "Day 2 severe sepsis post-Hartmann. He is oozing from four device sites, the gums and the abdominal dressing. Platelets down 140 to 62, PT prolonged 4 seconds, fibrinogen down 1.4 to 0.8, D-dimer strongly elevated, schistocytes on the smear — ISTH score 6. Urine output is down to about 24 mL/h, his fingertips are dusky, and he was less responsive at the sedation hold. Requesting review for component support and reassessment of source control." The traps to avoid: reading the falling urine output as a fluid problem and simply giving more volume when it is an organ-failure cue; attributing the reduced responsiveness to sedation when the sources name stroke among the complications; and expecting any anticoagulant here, because the instinct that "DIC is treated with heparin" is true only on the other phenotype.

  6. 6
    Evaluate

    Success over the next hours: the bleeding sites reduce in number rather than simply being re-dressed, platelets and fibrinogen stabilize or rise after component support, PT shortens, urine output climbs back, capillary refill improves, and the patient regains his previous level of responsiveness at the next sedation hold. Crucially, the sepsis parameters improve too — if they do not, the DIC will not either. Re-escalation triggers are set in advance: any new bleeding site, oral purpura or gross hematuria; a further fall in platelets or fibrinogen on the next panel; urine output that keeps falling; progression of the digital duskiness toward necrosis; or any further neurological deterioration. And the sobering frame for the family conversation: DIC doubles the mortality of the sepsis that caused it, and survivors face a prolonged recovery.

Scenario — you’re the nurse

Work each question before revealing the answer. Rationales explain the wrong options too.

Medical ICU · 0430, hospital day 2

A 58-year-old man admitted 36 hours ago with severe sepsis from a perforated diverticulum, now post-operative after a Hartmann procedure. He is intubated and sedated, on norepinephrine, with an arterial line, a right internal jugular central line, two peripheral cannulas, and a urinary catheter. Overnight the bedside nurse has noticed that the oral care swab keeps coming away pink.

0430 vitals — HR 118 · BP 92/48 on norepinephrine · RR 22 (ventilated) · T 38.4 °C · SpO₂ 94% on FiO₂ 0.5
Assessment — oozing from the arterial line site, both peripheral cannula sites, and the central line dressing · gums bleed with oral care · abdominal dressing has fresh serosanguinous staining · fingertips dusky with sluggish capillary refill
Urine output — 95 mL over the last 4 hours, down from 45 mL/h yesterday · urine pink-tinged
Labs now vs admission — platelets 62 (was 140) × 10⁹/L · PT 16.4 s against a control of 12.4 s — prolonged by 4 seconds, a ratio of about 1.3 · fibrinogen 0.8 g/L (was 1.4) · D-dimer strongly elevated · smear: schistocytes present
Chart — sedation held at 0400, patient did not follow commands as he did yesterday · no anticoagulant currently prescribed · surgeon aware of abdominal dressing staining
Q1 Multiple choice
Using the ISTH overt DIC score — platelets 62 × 10⁹/L, D-dimer strongly elevated, PT prolonged by 4 seconds, fibrinogen 0.8 g/L — what is the score, and what does it indicate?
  1. A. Score 3 — below the threshold, DIC is unlikely
  2. B. Score 6 — compatible with overt DIC
  3. C. Score 8 — the maximum score, indicating fulminant DIC
  4. D. The score cannot be calculated without an aPTT result
Reveal answer & rationale
Answer: B
Platelets 62 is below 100 but not below 50, scoring 1; a strong D-dimer rise scores 3; PT prolonged 4 seconds falls in the 3 to under 6 seconds band, scoring 1; fibrinogen 0.8 g/L is below 1 g/L, scoring 1 — a total of 6, and 5 or more is compatible with overt DIC (B). (A) undercounts, most likely by scoring the D-dimer as a moderate rather than strong rise. (C) overcounts; 8 is not this patient’s score, and the score describes likelihood rather than grading fulminance. (D) is the trap: the score uses PT, not aPTT — the ISTH prefers PT precisely because aPTT can be falsely shortened by acute-phase factor VIII elevation and its prolongation may lag behind the clinical picture. Remember too that the score is only applied when an underlying DIC-associated condition exists, and that its positive predictive value depends on where you land: 47% at exactly 5, 68% at 6 — this patient — and 88% at 7 or above. Note also that this is the 2001 ISTH score; the society issued updated criteria in 2025 whose full point table is not openly published.
Q2 Select all that apply
Which findings in this patient represent the thrombotic arm of DIC rather than the bleeding arm? Select all that apply.
  1. A. Urine output down to about 24 mL/h with pink-tinged urine
  2. B. Dusky fingertips with sluggish capillary refill
  3. C. Reduced responsiveness at the sedation hold
  4. D. Oozing from the arterial line and both peripheral cannula sites
  5. E. Bleeding gums with oral care
Reveal answer & rationale
Answer: A, B, C
Falling urine output (A) reflects renal microthrombi and hypoperfusion and is an organ-failure cue, not a fluid cue. Dusky fingertips with poor refill (B) are clots that "reduce or block blood flow" — the distal circulation being occluded by the same microthrombi. Reduced responsiveness (C) reflects cerebral involvement, with stroke named among the complications. Line-site oozing (D) and bleeding gums (E) are the consumptive bleeding arm — real, urgent, and the reason the patient was noticed, but not the thrombotic half. The teaching point is that both arms run in the same patient simultaneously, and the thrombotic findings are the ones most easily attributed to sepsis, sedation, or dehydration.
Q3 Multiple choice
A colleague asks why heparin has not been ordered, saying "DIC is a clotting problem, so anticoagulation is the treatment." The best response is:
  1. A. "Heparin is always contraindicated in DIC because the patient is bleeding."
  2. B. "Heparin is phenotype-dependent — it is not recommended in the bleeding or massive-bleeding types, and in sepsis it has not reduced organ injury or mortality while increasing bleeding risk."
  3. C. "Heparin would be given, but only after the platelet count recovers above 100."
  4. D. "Heparin is unnecessary because fresh frozen plasma already provides anticoagulation."
Reveal answer & rationale
Answer: B
The sourced position is conditional and depends on which arm the patient is on (B): heparin "is not recommended in patients with bleeding or massive bleeding type of DIC due to the increased risk of bleeding," while it is recommended in the non-symptomatic pre-DIC type and when there is extensive clotting; and in sepsis specifically, a meta-analysis of nine trials found it "does not reduce organ injury or mortality, but was associated with an increase in the risk of bleeding." (A) overstates into a blanket contraindication and loses the phenotypes where heparin is correct — including prophylaxis for the DIC patient who is not actively bleeding. (C) invents a platelet threshold that no source attaches to heparin. (D) is pharmacologically backwards: fresh frozen plasma replaces clotting factors, it does not anticoagulate. Note one related rule: if antithrombin concentrate is given, it must be without concomitant heparin.
Q4 Multiple choice
The fibrinogen was 1.4 g/L on admission — within many reference ranges — and is now 0.8 g/L. What does this illustrate?
  1. A. The admission value was a laboratory error, since fibrinogen is never normal in DIC
  2. B. Fibrinogen is an acute-phase reactant, so it can read normal early while consumption is already underway — the falling trend is the finding, not the threshold
  3. C. Fibrinogen is unreliable in DIC and should not be monitored
  4. D. The change is clinically meaningless because both values are above the transfusion threshold
Reveal answer & rationale
Answer: B
Absolute low fibrinogen has only 22% sensitivity for DIC precisely because fibrinogen "is also an acute-phase reactant" — in a septic patient it may start elevated and fall steeply while still passing through the normal range, so clinicians are told to watch "a decreasing fibrinogen level" (B). (A) is wrong: a normal early fibrinogen is expected behaviour, not an error. (C) inverts the lesson — fibrinogen is one of the four scored ISTH components and is monitored precisely because of its trend. (D) fails twice: the change is exactly the clinically meaningful part, and no fetched source gives a general fibrinogen transfusion trigger for DIC outside the APL setting. This is the clearest illustration of the page’s core diagnostic rule: serial testing is the diagnosis, not a single panel.
Q5 Put in order
Put the nurse’s priorities in order for this patient:
  1. A. Confirm with the team that source control and antimicrobial therapy for the sepsis are adequate
  2. B. Escalate with the full picture — bleeding sites, lab trend and score, falling urine output, dusky digits, reduced responsiveness
  3. C. Anticipate and administer ordered component support — platelets, with plasma if the PT ratio reaches the 1.5 times normal trigger
  4. D. Secure large-bore venous access, apply bleeding precautions, and hold non-essential punctures
Reveal answer & rationale
Correct order: D → B → A → C
Protect the access and the skin first (D) — securing large-bore access while the patient can still be cannulated is the one procedural instruction the nursing literature gives, and every further puncture creates a site that will not seal. These need no order. Escalate next (B), because the drug and transfusion decisions ahead are phenotype-dependent and the picture includes organ dysfunction, not just bleeding. Source control (A) is the actual treatment — DIC is always secondary and will not resolve while the sepsis runs — but it is a team action that follows from the escalation rather than something the nurse performs alone at the bedside. Component support (C) is real and necessary but it is holding the line rather than fixing the disease, and it depends on orders generated by the escalation. Reversing (C) and (B) would mean transfusing without the team knowing the organ-dysfunction picture; placing (A) first would delay every bedside protection while a systems conversation happens.

Common questions

What causes disseminated intravascular coagulation?
Common causes and risk factors include sepsis — the most common cause; dic occurs in up to 30% to 50% of cases of severe sepsis, malignancy — up to 20% of patients with metastatic adenocarcinoma or lymphoproliferative disease, acute promyelocytic leukemia — the leukemia that presents as a coagulation emergency, placental abruption, hellp syndrome, and others.
What are the early signs of disseminated intravascular coagulation?
Early findings include Bleeding from several unrelated sites at once — gingiva, surgical or trauma sites, vagina, rectum, and around devices such as cannulas, arterial lines and urinary catheters, Platelets, PT, fibrinogen, and D-dimer all moving in the wrong direction together.
Which findings should a nurse report immediately in disseminated intravascular coagulation?
Report immediately: Bleeding from several unrelated sites at once — gingiva, surgical or trauma sites, vagina, rectum, and around devices such as cannulas, arterial lines and urinary catheters, Skin necrosis, gangrene, and cyanosis of the extremities, Falling urine output, then oliguria or anuria, with hematuria, New confusion or a change in level of consciousness, Oral mucosal hemorrhage, purpura, and extremity petechiae in a newly diagnosed leukemia, and others. These signal deterioration that needs rapid intervention.
How can a patient be clotting and bleeding at the same time?
They are the same process seen from two ends. Tissue factor triggers thrombin and fibrin generation throughout the circulation, throwing microthrombi into small vessels — which is the clotting you cannot see, showing up as falling urine output, confusion, and dusky digits. Producing those clots consumes the platelets and clotting factors, and consumes the natural anticoagulants (the protein C system and antithrombin III) alongside them. So the patient who is clotting everywhere simultaneously cannot clot where it matters, and bleeds from every line site, the gums, and the surgical wound. Nothing is wrong with the platelets that remain — there are simply not enough of them left, because they were spent in vessels too small to see.
Why would anyone give heparin to a patient who is bleeding — and when is it actually given?
The logic of the paradox is sound: the bleeding is caused by uncontrolled thrombin generation, so interrupting the clotting could stop the consumption that produces the hemorrhage. But the fetched evidence makes it phenotype-dependent, not universal. Heparin is recommended in the non-symptomatic (pre-DIC) type, when there is extensive clotting, and as prophylaxis in DIC patients who are not actively bleeding. It is not recommended in the bleeding or massive-bleeding types "due to the increased risk of bleeding." And in sepsis specifically the evidence is unfavourable: a meta-analysis of nine trials found heparin "does not reduce organ injury or mortality, but was associated with an increase in the risk of bleeding." Where it is used, low molecular weight heparin is preferred over unfractionated. One related rule: antithrombin concentrate must be given without concomitant heparin, because heparin alters its protective effect.
What single laboratory habit catches DIC earliest?
Reading the trend, not the number. "A combination of results at different time points is particularly helpful in determining the presence of DIC," and serial monitoring provides "a safeguard for the early recognition of DIC" even when the initial values look normal. Three specific traps make the single-panel approach fail: fibrinogen is an acute-phase reactant with only 22% sensitivity as an absolute value, so it can read normal while consumption is well underway; aPTT can be falsely shortened by acute-phase factor VIII elevation, which is why the ISTH prefers PT; and D-dimer assays have different, non-interchangeable normal ranges between laboratories, so a patient is best compared with their own previous result. Platelets, PT, fibrinogen and D-dimer moving the wrong way together, over hours, is the diagnosis.

Sources

Reviewed by Hae Suk Lee, RN

Educational summary for nursing students. Scenarios are fictional teaching cases. Always verify against current guidelines and your institution's protocols before acting in practice. Not medical advice.

Bookmark LearnDrugs.com?

Your saved pages are kept in this browser. Add LearnDrugs.com to your browser’s bookmarks to get back to them in one click.

Drag this link to your bookmarks bar: LearnDrugs.com

Or press Ctrl + D to bookmark the page you’re on.